Original Studies
Respiratory Syncytial Virus Disease in Preterm Infants in the US Born at 32–35 Weeks Gestation Not Receiving Immunoprophylaxis Christopher S. Ambrose, MD,* Evan J. Anderson, MD,† Eric A. F. Simões, MBBS, DCH, MD,‡ Xionghua Wu, PhD,§ Hanaa Elhefni, MD, MS, MPH,§ C. Lucy Park, MD,¶ Frangiscos Sifakis, PhD, MPH,§|| and Jessie R. Groothuis, MD§ Background: The Respiratory Syncytial Virus (RSV) Respiratory Events Among Preterm Infants Outcomes and Risk Tracking (REPORT) study evaluated RSV disease burden in US preterm infants 32–35 weeks gestational age (wGA) not receiving RSV prophylaxis. Methods: Preterm infants
Respiratory Syncytial Virus Disease in Preterm Infants in the US Born at 32–35 Weeks Gestation Not Receiving Immunoprophylaxis Christopher S. Ambrose, MD,* Evan J. Anderson, MD,† Eric A. F. Simões, MBBS, DCH, MD,‡ Xionghua Wu, PhD,§ Hanaa Elhefni, MD, MS, MPH,§ C. Lucy Park, MD,¶ Frangiscos Sifakis, PhD, MPH,§|| and Jessie R. Groothuis, MD§ Background: The Respiratory Syncytial Virus (RSV) Respiratory Events Among Preterm Infants Outcomes and Risk Tracking (REPORT) study evaluated RSV disease burden in US preterm infants 32–35 weeks gestational age (wGA) not receiving RSV prophylaxis. Methods: Preterm infants
